Manchester Peptides gold M logoMANCHESTERPEPTIDES
24/7 enquiries
UK research catalogueThird-party COAsEvidence-led guides24/7 enquiries
Next Day Guaranteed Delivery
← BackManchester Peptides gold M logo

Weight Loss

Retatrutide and Tirzepatide, together in one collection. Browse each pen and vial format, compare strengths and prices, or open a card for research information and related laboratory reports.

3 options

Vial · 30 mg

Retatrutide

An investigational triple receptor agonist designed to act on GLP-1, GIP and glucagon pathways.

£85
Product information

An investigational triple receptor agonist designed to act on GLP-1, GIP and glucagon pathways. Researchers are studying how this combined signalling may affect appetite, glucose regulation, energy balance and body composition. It is not currently an approved UK medicine.

Evidence and sources at a glance
Human evidence
Randomised phase 2 evidence and reported phase 3 results are available. Check whether a particular result is a peer-reviewed publication or a sponsor announcement, and inspect its population and follow-up.
Regulatory context
Retatrutide is not currently an authorised UK medicine. Investigational status should never be presented as approval.
Read the full evidence map
Related laboratory reports30 mg COA · #17289530 mg COA · #134840Reports describe the tested samples; batch identity must be matched separately.
Lilly: current retatrutide research programmeRead the Retatrutide research guide →For research and reference purposes only. Listing a product does not establish suitability for medical use.
View full details

Pen · 40 mg

Retatrutide

An investigational triple receptor agonist designed to act on GLP-1, GIP and glucagon pathways.

£140
Product information

An investigational triple receptor agonist designed to act on GLP-1, GIP and glucagon pathways. Researchers are studying how this combined signalling may affect appetite, glucose regulation, energy balance and body composition. It is not currently an approved UK medicine.

Evidence and sources at a glance
Human evidence
Randomised phase 2 evidence and reported phase 3 results are available. Check whether a particular result is a peer-reviewed publication or a sponsor announcement, and inspect its population and follow-up.
Regulatory context
Retatrutide is not currently an authorised UK medicine. Investigational status should never be presented as approval.
Read the full evidence map
Related laboratory reports40 mg COA · #195385Reports describe the tested samples; batch identity must be matched separately.
Lilly: current retatrutide research programmeRead the Retatrutide research guide →For research and reference purposes only. Listing a product does not establish suitability for medical use.
View full details

Pen · 40 mg

Tirzepatide

A dual GIP and GLP-1 receptor agonist associated with appetite, insulin and glucose-regulation pathways.

£140
Product information

A dual GIP and GLP-1 receptor agonist associated with appetite, insulin and glucose-regulation pathways. Authorised prescription versions have established clinical uses, but unlicensed research material is not equivalent to an approved medicine.

Evidence and sources at a glance
Human evidence
Multiple phase 3 trials and real-world use provide a much larger evidence base than is available for most catalogue peptides.
Regulatory context
Authorised tirzepatide medicines have approved indications and controlled supply routes; research material is not equivalent.
Read the full evidence map
NHS: tirzepatideRead the Tirzepatide research guide →For research and reference purposes only. Listing a product does not establish suitability for medical use.
View full details
Research references (2)

Metabolic peptide research explained

Metabolic peptide research examines signalling pathways involved in appetite, satiety, glucose regulation, insulin response and energy balance. Retatrutide and tirzepatide are not interchangeable: retatrutide is an investigational triple agonist acting at GLP-1, GIP and glucagon receptors, while tirzepatide acts at GIP and GLP-1 receptors.

A catalogue strength describes the labelled amount and format. It does not establish clinical suitability, authenticity or equivalence to an authorised medicine. Where a third-party laboratory report is supplied, the report should be matched to its named sample and read alongside the exact methods and measured results.

Common research questions

What is the difference between Retatrutide and Tirzepatide?

Retatrutide is an investigational GLP-1, GIP and glucagon receptor agonist. Tirzepatide acts at GIP and GLP-1 receptors and is used in authorised prescription products for specific indications.

Does a labelled strength prove what a sample contains?

No. The label states an intended amount. Analytical testing of the identified sample is needed to provide evidence about identity, measured quantity or purity.